Being in Phase 2 at this point, even if they were in the same arena of treatment why would it be a threat? How many years from approval can this drug be? I just don't get all of the consternation about a late phase 2 drug with very few clinical patients.

I have to admit I have been lazy regarding the prospects of this drug but it seems like we ought to worry more about a cure for diabetes in the first few years of Afrezza sales. In other words. we shouldn't IMO.

http://www.oramed.com/ufiles/phase_2a_isr.pdf

Swing